Does the occurrence of sensory neuropathy in this patient affect your choice for second-line treatment?

Ki Chung, MD: Impact of Sensory Neuropathy on Second-Line Treatment

Would you consider an epidermal growth factor receptor (EGFR)-directed therapy in this patient, and does her mutational status affect your decision?

Ki Chung, MD: EGFR-Directed Therapy and Mutational Status

Should anti-angiogenesis therapy be continued in this patient?

Ki Chung, MD: Continuation of Anti-Angiogenesis Therapy

What second-line options are available to prolong survival in patients like Diane with recurrent mCRC?

Ki Chung, MD: Second-Line Options to Prolong Survival

Alan Venook, MD: Impact of Sensory Neuropathy on Second-Line Treatment

Alan Venook, MD: EGFR-Directed Therapy and Mutational Status 

Alan Venook, MD: Continuation of Anti-Angiogenesis Therapy 

Alan Venook, MD:  Second-Line Options to Prolong Survival

Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center, says the development of sensory neuropathy definitely impacts her decision-making process regarding second-line therapy. In this setting with a rising carcinoembryonic antigen (CEA), Eng would consider starting FOLFIRI. If the patient is opposed to alopecia, she would consider reinitiation of oxaliplatin (FOLFOX) with the consideration of a dose reduction from 85 mg/m2 to 65 mg/m2. Eng would also consider starting treatment with an antineuropathic agent, in order to address the patient's grade 1 neuropathy.

Cathy Eng, MD, FACP: Impact of Sensory Neuropathy on Second-Line Treatment

Would you consider an EGFR-directed therapy in this patient, and does her mutational status affect your decision?

Cathy Eng, MD, FACP: EGFR-Directed Therapy and Mutational Status

Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center, says anti-angiogenic therapy could definitely be continued in this patient. It&rsquo;s been demonstrated in prior studies that continuing beyond progression from first-line therapy does benefit patients in regards to the continuation of anti-angiogenic therapy, in combination with chemotherapy. Bevacizumab could be continued. Other antiangiogenic agents could be considered as well, such as ramucirumab and ziv-aflibercept, in combination with irinotecan-based therapy

Cathy Eng, MD, FACP: Continuation of Anti-Angiogenesis Therapy

What second-line options are available to prolong survival in patients, like Diane, with recurrent mCRC?

Metastatic Colorectal Cancer: Part 1

New content coming soon, please check back later.